Drug Search Results
More Filters [+]

Guadecitabine

Alternative Names: guadecitabine, sgi-110
Latest Update: 2024-05-16
Latest Update Note: Clinical Trial Update

Product Description

A dinucleotide antimetabolite of a decitabine linked via phosphodiester bond to a guanosine, with potential antineoplastic activity. Following metabolic activation by phosphorylation and incorporation into DNA, guadecitabine inhibits DNA methyltransferase, thereby causing genome-wide and non-specific hypomethylation and inducing cell cycle arrest at S-phase. This agent is resistant to cytidine deaminase, hence may result in gradual release of decitabine both extra- and intracellularly, leading to more prolonged exposures to decitabine. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/guadecitabine)

Mechanisms of Action: DNA Mtase Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Astex
Company Location: DUBLIN CA 94568
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Guadecitabine

Countries in Clinic: Italy, Japan, United Kingdom, United States

Active Clinical Trial Count: 9

Highest Development Phases

Phase 2: Acute Monocytic Leukemia|Acute Myeloid Leukemia|Acute Myelomonocytic Leukemia|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Kidney Cancer|Melanoma|Myelodysplastic Syndrome|Myeloproliferative Disorders|Non-Small-Cell Lung Cancer|Renal Cell Carcinoma|Small Cell Lung Cancer|Transitional Cell Carcinoma

Phase 1: Lung Cancer|Prostate Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

HyPeR

P1

Recruiting

Prostate Cancer|Non-Small-Cell Lung Cancer

2026-09-01

DOSE SELECTION

P1

Active, not recruiting

Lung Cancer

2024-07-01

NIBIT-ML1

P2

Not yet recruiting

Melanoma|Non-Small-Cell Lung Cancer

2023-03-01

BTCRC-GU16-043

P2

Active, not recruiting

Kidney Cancer|Renal Cell Carcinoma

2022-12-01

Recent News Events